Juno Therapeutics Appoints Hal Barron, M.D. To Board Of Directors

SEATTLE (October 1, 2014) – Juno Therapeutics, Inc. today announced the appointment of Hal Barron, M.D., President of Research & Development at Calico, to its Board of Directors. 

"Hal is one of the most respected clinician-scientists and successful drug developers in the biotechnology industry. His unique perspective and experiences at Genentech and Roche, particularly in oncology, will bring valuable insights to our team as we work to bring our CAR and TCR product candidates to patients and disrupt the treatment of cancer," said Juno CEO Hans Bishop. 

Dr. Barron is currently President of Research & Development at Calico (California Life Sciences LLC), a Google-founded research and development company. Previously, he served as Executive Vice President and Chief Medical Officer at Genentech and Roche. He received his bachelor's degree from Washington University in St. Louis, his medical degree from Yale University, and completed his training in medicine and cardiology at the University of California, San Francisco. 

"Juno is at the forefront of an exciting new area of medicine that aims to leverage recent insights in immunology and cell therapy to create meaningfully better cancer treatments," said Dr. Barron. "I look forward to working with Juno's board and management team to continue to accelerate the pace and breadth of development of the company's CAR and TCR technologies." 

### 

About Juno 

Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor (CAR) and high-affinity T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer. Juno has shown compelling efficacy in clinical trials using multiple cell-based product candidates to address refractory B cell lymphomas and leukemias. The company's long-term aim is to improve and leverage its technologies to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from three of the world's leading cancer centers – the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children's Research Institute. 

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.